GLIOBLASTOMA CLINICAL TRIALS
IN CHINA
China's GBM trial portfolio extends beyond anything available in most Western countries โ CAR-T targeting three antigens, oncolytic viruses, personalised neoantigen vaccines, and BNCT Phase III. International patients can access these trials through CancerFax.
analyticsAt a Glance
- check_circleCAR-T trials targeting EGFRvIII, GD2, and IL13Rฮฑ2 โ active Phase I/II enrolment
- check_circleOncolytic virus and neoantigen vaccine programmes active in Beijing and Shanghai
- check_circleBNCT Phase III vs standard Stupp for newly diagnosed GBM โ China and Japan
- check_circleInternational patients accepted โ CancerFax coordinates eligibility and enrolment
Why China Leads in GBM Clinical Trial Innovation
China's combination of large patient population, rapid regulatory reform (NMPA has accelerated oncology trial approvals), major government investment in cell therapy and immunotherapy research, and manufacturing capacity for personalised cellular treatments has created a uniquely rich GBM investigational ecosystem.
Faster Trial Approval and Enrolment
China's NMPA (National Medical Products Administration) has significantly accelerated oncology trial approvals since 2017 โ reducing the time from Phase I IND to first patient enrolled. Major Chinese academic centres can enrol GBM patients faster than most Western sites given their high patient volume. This speed means more trials reach Phase II and III in China than in equivalent Western populations.
Cell Therapy Manufacturing Infrastructure
CAR-T therapy requires patient-specific cell manufacturing โ China has invested heavily in GMP cell therapy production facilities at or near trial centres. This enables faster manufacturing timelines and lower production costs than many Western CAR-T programmes. Oncolytic virus manufacturing and personalised neoantigen vaccine production are similarly well-resourced at Chinese academic centres.
Active GBM Clinical Trial Categories in China
A summary of the major investigational therapy categories actively enrolling GBM patients at Chinese academic centres, including typical eligibility criteria for each.
| Trial Category | Target / Agent | Setting | Key Eligibility | Leading Centres |
|---|---|---|---|---|
| CAR-T cell therapy | EGFRvIII-directed CAR-T (intratumoral or IV) | Newly diagnosed + recurrent EGFRvIII+ GBM | EGFRvIII amplification confirmed; ECOG 0โ2; prior surgery | PUMCH, Xuanwu, Tiantan (Beijing) |
| CAR-T cell therapy | GD2-directed CAR-T | Recurrent GBM (GD2+ confirmed) | GD2 expression โฅ1+; prior Stupp protocol; ECOG 0โ2 | Huashan (Shanghai), PUMCH |
| CAR-T cell therapy | IL13Rฮฑ2-CAR-T (intracavitary delivery) | Recurrent GBM | IL13Rฮฑ2 IHC positive; prior resection with Ommaya placement possible | Beijing trial sites |
| Oncolytic virus | M1 virus (intralesional) | Recurrent GBM | Accessible tumour for direct injection; ECOG 0โ2; no active infection | Huashan, Zhongshan (Shanghai) |
| Oncolytic virus | Delta-24-RGD (intracavitary) | Recurrent GBM with resection cavity | Prior surgical resection; Ommaya placement; ECOG 0โ1 | Beijing academic centres |
| Neoantigen vaccine | Personalised peptide vaccine + PD-1 | Newly diagnosed MGMT-methylated GBM | MGMT methylated; TMB โฅ5; adequate immune function; NGS complete | PUMCH, Tiantan |
| BNCT Phase II/III | BPA-based BNCT (newly diagnosed + recurrent) | Newly diagnosed GBM vs Stupp (Phase III); recurrent post-CRT (Phase II) | ยนโธF-BPA PET positive; ECOG 0โ2; no prior BNCT | Xiamen Humanity Hospital, Beijing BNCT |
| PD-1 + radiation combination | Camrelizumab/sintilimab + RT + TMZ | Newly diagnosed MGMT-methylated or unmethylated GBM | No prior immunotherapy; ECOG 0โ1; brain MRI at baseline | Multiple Chinese academic centres |
Why Molecular Profiling Is Essential Before Trial Matching
Most GBM trials in China have molecular eligibility requirements that cannot be determined from standard pathology alone โ comprehensive NGS profiling is the prerequisite for accessing the broadest range of trials.
Key Markers for GBM Trial Eligibility
MGMT methylation status โ required for many vaccine and immunotherapy trials. IDH1/2 mutation โ distinguishes true GBM from IDH-mutant glioma (different trial eligibility). EGFRvIII mutation โ CAR-T trial eligibility (EGFRvIII amplification). EGFR amplification (without EGFRvIII) โ tyrosine kinase inhibitor trial eligibility. Tumour mutational burden (TMB) โ immunotherapy trial eligibility. GD2 expression (IHC) โ GD2 CAR-T eligibility. PTEN mutation, VEGFR โ additional trial-specific markers.
If You Don't Have NGS โ What to Do
If comprehensive molecular profiling has not been performed, CancerFax can identify appropriate NGS testing laboratories that work with archived FFPE tissue from prior biopsy. For patients without tissue for NGS, liquid biopsy (ctDNA from blood) can identify key mutations with less sensitivity. CancerFax recommends completing NGS before trial matching โ without it, at least 60% of potential trial eligibility pathways cannot be assessed.
How CancerFax Connects GBM Patients to Chinese Trials
CancerFax performs systematic, molecularly-informed trial matching โ not a generic list of open GBM studies, but a shortlist of trials for which you specifically appear eligible based on your molecular profile and treatment history.
- 1
Step 1: Upload Your Complete Records
MRI brain (DICOM preferred), pathology report with WHO grade and molecular markers, prior treatment records (surgery, RT dose/fractions, chemotherapy cycles), performance status, and current medications. The more complete the records, the more accurate the trial matching.
- 2
Step 2: Molecular Profile-Based Trial Matching
CancerFax's oncology team matches your specific molecular profile โ MGMT, IDH, EGFRvIII, TMB, GD2, and other markers โ against eligibility criteria for open GBM trials at Chinese academic centres. We identify trials where your profile meets the inclusion criteria and exclude trials where known exclusion criteria apply.
- 3
Step 3: Trial Summary and Shortlist
You receive a written report identifying 2โ5 potentially eligible trials โ with explanation of why each trial applies to your case, what participation involves (visit schedule, treatment, monitoring), and what the experimental treatment aims to achieve.
- 4
Step 4: Pre-Screening Submission
CancerFax submits your clinical summary to the trial site's principal investigator for pre-screening review โ confirming whether the trial team believes you are likely eligible before you commit to travel to China for formal screening.
- 5
Step 5: China Access and Enrolment Coordination
If pre-screening is positive, CancerFax coordinates formal screening visit scheduling, medical visa letter, accommodation, and interpreter support. On enrolment, we remain your case manager throughout trial participation โ communicating between you, the trial site, and your home oncologist.
Trial Options: Newly Diagnosed vs Recurrent GBM
Trial availability differs significantly between newly diagnosed and recurrent GBM โ the molecular and treatment history requirements create different eligibility landscapes.
Newly Diagnosed GBM Trials
- BNCT vs Stupp Phase III (MGMT any)Head-to-head comparison โ no prior treatment required; enrolling now at Xiamen and Chinese BNCT centres
- PD-1 + RT + TMZ combination trials (MGMT-methylated)Immunotherapy added to standard Stupp โ MGMT methylation typically required for enhanced immune signal
- Neoantigen vaccine + Stupp + adjuvant TMZPersonalised vaccine manufactured from NGS data + standard Stupp โ NGS at diagnosis required
- TTFields + novel systemic agent combinationsAdding TTFields to new systemic agents beyond bevacizumab โ EF-14 platform extension trials
Recurrent GBM Trials
- CAR-T (EGFRvIII, GD2, IL13Rฮฑ2) โ Phase I/IIRequires confirmed antigen expression; โฅ1 prior line; ECOG 0โ2; intratumoral delivery requires Ommaya
- Oncolytic virus (M1, Delta-24) โ Phase I/IIAccessible tumour for injection; accessible cavity for intracavitary delivery; no active systemic infection
- BNCT โ Phase II (post-Stupp)After prior chemoradiation; BPA PET positive; ECOG 0โ2; accessible to neutron beam coverage
- Checkpoint inhibitor re-challenge ยฑ novel partnerFor patients not previously exposed to PD-1 inhibitors with MGMT-methylated or MSI-H recurrent GBM
Related GBM Trial and Treatment Resources
Further guides on GBM treatment options and clinical trial access.
Frequently Asked Questions
GBM Clinical Trials in China
Can international GBM patients join Chinese clinical trials?
Yes โ Chinese GBM clinical trials at major academic centres including PUMCH, Tiantan, Xuanwu, and Huashan Hospital accept international patients, provided they meet the trial's eligibility criteria. The key requirements are: completing formal screening at the trial site in China; having a valid Chinese medical visa; being able to attend the required visit schedule (treatment and monitoring visits); and meeting all molecular eligibility criteria. CancerFax coordinates the pre-screening submission, visa documentation, and trial site communication for international patients to streamline the enrolment process.
What is the difference between CAR-T trials in China vs the USA for GBM?
Several practical differences: Chinese CAR-T programmes for GBM tend to use intratumoral (via Ommaya reservoir) or intraventricular delivery alongside or instead of systemic IV infusion โ aiming to bypass the blood-brain barrier and deliver high local CAR-T concentrations directly to the tumour microenvironment. Manufacturing timelines are often faster at Chinese centres given established GMP infrastructure. The antigen targets are similar (EGFRvIII, GD2, IL13Rฮฑ2) but specific construct designs differ between programmes. Cost of trial participation (treatment) is zero in all cases โ the experimental agent is sponsor-provided. US trials also exist in parallel โ CancerFax advises on the most appropriate programme based on your specific molecular profile and logistical situation.
If I join a Chinese GBM trial, what happens to my standard-of-care treatment?
Trials are designed around standard-of-care treatment, not instead of it. For newly diagnosed GBM trials, the experimental arm typically adds a new agent to the Stupp protocol โ you receive standard TMZ and RT plus the trial treatment. For recurrent GBM trials, you may receive the experimental agent alongside standard salvage therapy (bevacizumab, CCNU) or as monotherapy depending on trial design. A detailed treatment plan is reviewed and agreed before enrolment. CancerFax ensures your home oncologist receives the full trial protocol and treatment records so continuing standard care at home after trial-related treatment is completed is coordinated seamlessly.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Is There a GBM Clinical Trial in China That Matches Your Profile?
Upload your NGS report, MRI, pathology, and treatment history. CancerFax will perform molecular profile-matched trial screening against active Chinese GBM studies and connect you with trial sites accepting international patients.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.